Brazikumab Antibody

SKU: orb1980510

Description

Brazikumab (AMG 139) is a humanized monoclonal antibody and selective IL-23 antagonist that binds the p19 subunit. It is a research tool for investigating Crohn's disease pathogenesis, with applications in both in vitro mechanistic studies and in vivo preclinical models.

Research Area

Immunology & Inflammation

Images & Validation

−

Key Properties

−

CAS Number	1610353-18-8
MW	145.78 kDa
Purity	95.00%
Target	Interleukin,IL Receptor

Bioactivity

−

Target IC50

IL-23:0.138 nM (Kd)

In Vitro

Brazikumab is a human IgG2 monoclonal antibody that binds to the p19 subunit with high affinity and has a KD of 0.138 nM against human IL-23. Brazikumab inhibits the binding of recombinant and natural IL-23 to receptors that are stably expressed in COS cells with IC50 of 188 and 284 pM, respectively. Brazikumab inhibits in vitro production of IFN-γ in NK cells stimulated by human natural or recombinant IL-23 (bound to IL-18) with IC50 of 238 and 93 pM, respectively.

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

MEDI 2070, MEDI2070, AMG139, AMG 139

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

Interleukin,IL Receptor

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols